National Cancer Institute
U.S. National Institutes of Health |

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
About NCI
Monitoring the Safety of Clinical Trials
    Posted: 02/06/2001    Reviewed: 05/01/2006

Monitoring the Safety of Clinical Trials

Who's Responsible?

What Are IRBs?



Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Related Pages
Protecting Participants in Clinical Trials
A collection of material about the ways in which clinical trials participants are protected before and during the conduct of a study.

Monitoring NCI-Sponsored Clinical Trials
Protections for patients in cancer studies come into play at various times before and during a clinical trial. Before a trial can start enrolling patients, for example, it must be approved by an Institutional Review Board (IRB), located at the hospital or other site where the study will be conducted.
Monitoring the Safety of Clinical Trials

If you are thinking about participating in a clinical trial, you probably have a few important questions weighing on your mind: Is there a system in place to make sure this is a worthwhile study that does not subject people to unnecessary risks? In other words, who is checking up on the research team? What if things don't turn out the way that investigators are expecting they will? Who is watching out for any unexpected problems? Who is making sure that participants are protected? This guide is designed to answer those questions.

Next Section >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health